Top

Published in:

01-09-2011 | Original Article

Milk casein-derived tripeptides, VPP and IPP induced NO production in cultured endothelial cells and endothelium-dependent relaxation of isolated aortic rings

Authors: Tatsuhiko Hirota, Atsuko Nonaka, Akiko Matsushita, Naoto Uchida, Kohji Ohki, Masanori Asakura, Masafumi Kitakaze

Published in: Heart and Vessels | Issue 5/2011

Abstract

Milk casein-derived tripeptides, valyl prolyl proline (VPP), and isoleucyl prolyl proline (IPP) inhibit angiotensin-converting enzyme (ACE) and both fermented milk and proteolytic hydrolysates of milk casein containing these peptides exert blood pressure-lowering effects in animals and humans. On the top of these results, we have recently reported that the hydrolysate of milk casein containing both VPP and IPP improved the vascular endothelial function of subjects with stage I hypertension, enforcing us to elucidate the mechanism of the improvement of endothelial dysfunction by these peptides. For this purpose, we examined the effect of VPP and IPP on induction of nitric oxide (NO) production using cultured vascular endothelial cells and isolated arterial vessels. When both VPP and IPP were added to the medium of cultured endothelial cells at final concentrations of more than 100 nmol/l, the NO_x (NO₂ and NO₃) concentration in the medium was significantly higher than that of the control. Moreover, both VPP and IPP induced endothelium-dependent relaxation of isolated aortic rings, and these effects were inhibited by NO synthase inhibitors, K channel inhibitors, and bradykinin B2 receptor antagonists. These lines of results suggested that both VPP and IPP induced production of vasodilative substances including NO.

Alberti KG, Zimmet P, Shaw J (2006) Metabolic syndrome—a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 23(5):469–480PubMedCrossRef

Heitzer T, Schlinzig T, Krohn K, Meinertz T, Münzel T (2001) Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104(22):2673–2678 [Erratum in: Circulation 108(4):500]PubMedCrossRef

Venhoutte PM (1989) Endothelium and control of vascular function. State of the art lecture. Hypertension 13:658–667

Lucher TF (1990) Imbalance of endothelium-derived relaxing and contracting factors. A new concept in hypertension? Am J Hypertens 3:317–330

Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, Fishman MC (1995) Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377(6546):239–242PubMedCrossRef

Bogle RG, Coade SB, Moncada S, Pearson JD, Mann GE (1991) Bradykinin and ATP stimulate l-arginine uptake and nitric oxide release in vascular endothelial cells. Biochem Biophys Res Commun 180(2):926–932PubMedCrossRef

Buga GM, Gold ME, Fukuto JM, Ignarro LJ (1991) Shear stress-induced release of nitric oxide from endothelial cells grown on beads. Hypertension 17(2):187–193PubMed

Anderson EA, Mark AL (1989) Flow-mediated and reflex changes in large peripheral artery tone in humans. Circulation 79(1):93–100PubMedCrossRef

Higashi Y, Yoshizumi M (2003) New methods to evaluate endothelial function: method for assessing endothelial function in humans using a strain-gauge plethysmography: nitric oxide-dependent and -independent vasodilatation. J Pharmacol Sci 93(4):399–404PubMedCrossRef

10.

Schiffrin EL, Park JB, Intengan HD, Touyz RM (2000) Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 101(14):1653–1659PubMed

11.

John S, Schlaich M, Langenfeld M, Weihprecht H, Schmitz G, Weidinger G, Schmieder RE (1998) Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation 98(3):211–216PubMed

12.

Lonn E, Yusuf S, Dzavik V, Doris C, Yi Q, Smith S, Moore-Cox A, Bosch J, Riley W, Teo K, SECURE Investigators (2001) Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 103(7):919–925PubMed

13.

Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342(3):145–153 Erratum in: 2000 May 4;342(18):1376. N Engl J Med Mar 9;342(10):748PubMedCrossRef

14.

Stein JH, Keevil JG, Wiebe DA, Aeschlimann S, Folts JD (1999) Purple grape juice improves endothelial function and reduces the susceptibility of LDL cholesterol to oxidation in patients with coronary artery disease. Circulation 100(10):1050–1055PubMed

15.

Chan YH, Lau KK, Yiu KH, Li SW, Chan HT, Tam S, Shu XO, Lau CP, Tse HF (2007) Isoflavone intake in persons at high risk of cardiovascular events: implications for vascular endothelial function and the carotid atherosclerotic burden. Am J Clin Nutr 86(4):938–945PubMed

16.

Xu JY, Qin LQ, Wang PY, Li W, Chang C (2008) Effect of milk tripeptides on blood pressure: a meta-analysis of randomized controlled trials. Nutrition 24(10):933–940PubMedCrossRef

17.

Nakamura Y, Yamamoto N, Sakai K, Takano T (1995) Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin I-converting enzyme. J Dairy Sci 78(6):1253–1257PubMedCrossRef

18.

Hata Y, Yamamoto M, Ohni M, Nakajima K, Nakamura Y, Takano T (1996) A placebo-controlled study of the effect of sour milk on blood pressure in hypertensive subjects. Am J Clin Nutr 64(5):767–771PubMed

19.

Mizuno S, Matsuura K, Gotou T, Nishimura S, Kajimoto O, Yabune M, Kajimoto Y, Yamamoto N (2005) Antihypertensive effect of casein hydrolysate in a placebo-controlled study in subjects with high-normal blood pressure and mild hypertension. Br J Nutr 94(1):84–91PubMedCrossRef

20.

Hirota T, Ohki K, Kawagishi R, Kajimoto Y, Mizuno S, Nakamura Y, Kitakaze M (2007) Casein hydrolysate containing the antihypertensive tripeptides Val-Pro-Pro and Ile-Pro-Pro improves vascular endothelial function independent of blood pressure-lowering effects: contribution of the inhibitory action of angiotensin-converting enzyme. Hypertens Res 30(6):489–496PubMedCrossRef

21.

Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, Ducimetiere P, Benetos A (2001) Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 37(5):1236–1241PubMed

22.

Moncada S, Palmar RMJ, Higgs EA (1990) Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Toxicol 30:535–560CrossRef

23.

Asanuma H, Node K, Minamino T, Sanada S, Takashima S, Ueda Y, Sakata Y, Asakura M, Kim J, Ogita H, Tada M, Hori M, Kitakaze M (2003) Celiprolol increases coronary blood flow and reduces severity of myocardial ischemia via nitric oxide release. J Cardiovasc Pharmacol 4(41):499–505CrossRef

24.

Kitakaze M, Node K, Takashima S, Minamino T, Kuzuya T, Hori M (2000) Cellular mechanisms of cardioprotection afforded by inhibitors of angiotensin-converting enzyme in ischemic hearts: role of bradykinin and nitric oxide. Hypertens Res 23(3):253–259PubMedCrossRef

25.

Nakamura Y, Yamamoto N, Sakai K, Okubo A, Yamazaki S, Takano T (1995) Purification and characterization of angiotensin I-converting enzyme inhibitors from sour milk. J Dairy Sci 78(4):777–783PubMedCrossRef

26.

Hu S, Kim HS (1993) Activation of K⁺ channel in vascular smooth muscles by cytochrome P450 metabolites of arachidonic acid. Eur J Pharmacol 230(2):215–221PubMedCrossRef

27.

Matoba T, Shimokawa H, Kubota H, Morikawa K, Fujiki T, Kunihiro I, Mukai Y, Hirakawa Y, Takeshita A (2002) Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in human mesenteric arteries. Biochem Biophys Res Commun 290(3):909–913PubMedCrossRef

28.

Vanhoutte PM, Boulanger CM, Mombouli JV (1995) Endothelium-derived relaxing factors and converting enzyme inhibition. Am J Cardiol 76(15):3E–12EPubMedCrossRef

29.

Nakamura T, Mizutani J, Sasaki K, Yamamoto N, Takazawa K (2009) Beneficial potential of casein hydrolysate containing Val-Pro-Pro and Ile-Pro-Pro on central blood pressure and hemodynamic index: a preliminary study. J Med Food 12(6):1–6CrossRef

30.

Yoshizawa M, Maeda S, Miyaki A, Misono M, Choi Y, Shimojo N, Ajisaka R, Tanaka H (2009) Additive beneficial effects of lactotripeptides and aerobic exercise on arterial compliance in postmenopausal women. Am J Physiol Heart Circ Physiol 297:H1899–H1903PubMedCrossRef

31.

Yamaguchi N, Kawaguchi K, Yamamoto N (2009) Study of the mechanism of antihypertensive peptides VPP and IPP in spontaneously hypertensive rats by DNA microarray analysis. Eur J Pharmacol 620(1–3):71–77PubMedCrossRef

32.

Kaplan HR, Taylor DG, Olson SC, Andrews LK (1989) Quinapril—a preclinical review of the pharmacology, pharmacokinetics, and toxicology. Angiology 40(4 Pt 2):335–350PubMed

33.

Comini L, Bachetti T, Cargnoni A, Bastianon D, Gitti GL, Ceconi C, Ferrari R (2007) Therapeutic modulation of the nitric oxide: all ace inhibitors are not equivalent. Pharmacol Res 56(1):42–48PubMedCrossRef

34.

Toshiro M, Ueno T, Tanaka M, Oka H, Miyamoto T, Osajima K, Matsumoto K (2005) Antiproliferative action of an angiotensin I-converting enzyme inhibitory peptide, Val-Tyr, via an L-type Ca²⁺ channel inhibition in cultured vascular smooth muscle cells. Hypertens Res 28(6):545–552PubMedCrossRef

35.

Meluzin J, Vasku A, Kincl V, Panovský R, Srámková T (2009) Association of coronary artery disease, erectile dysfunction, and endothelial nitric oxide synthase polymorphisms. Heart Vessels 24(3):157–163PubMedCrossRef

36.

Ari H, Ari S, Erdogan E, Tiryakioğlu O, Üstündağ Y, Huysal K, Koca V, Bozat T (2010) A novel predictor of restenosis and adverse cardiac events: asymmetric dimethylarginine. Heart Vessels 25(1):19–26PubMedCrossRef

37.

Ohsawa K, Satsu H, Ohki K, Enjoh M, Takano T, Shimizu M (2008) Producibility and digestibility of antihypertensive beta-casein tripeptides, Val-Pro-Pro and Ile-Pro-Pro, in the gastrointestinal tract: analyses using an in vitro model of mammalian gastrointestinal digestion. J Agric Food Chem 56(3):854–858PubMedCrossRef

38.

Yamamoto N, Akino A, Takano T (1994) Antihypertensive effects of different kinds of fermented milk in spontaneously hypertensive rats. Biosci Biotechnol Biochem 58(4):776–778CrossRef

39.

Mizuno S, Nishimura S, Matsuura K, Gotou T, Yamamoto N (2004) Release of short and proline-rich antihypertensive peptides from casein hydrolyzate with an Aspergillus oryzae protease. J Dairy Sci 87(10):3183–3188PubMedCrossRef

40.

Meyer J, Bütikofer U, Walther B, Wechsler D, Sieber R (2009) Hot topic: changes in angiotensin-converting enzyme inhibition and concentrations of the tripeptides Val-Pro-Pro and Ile-Pro-Pro during ripening of different Swiss cheese varieties. J Dairy Sci 92(3):826–836PubMedCrossRef

41.

van der Pijl PC, Kies AK, Ten Have GAM, Duchateau GSMJE, Deutz NEP (2008) Pharmacokinetics of proline-rich tripeptides in the pig. Peptides 29(12):2196–2202PubMedCrossRef

Title: Milk casein-derived tripeptides, VPP and IPP induced NO production in cultured endothelial cells and endothelium-dependent relaxation of isolated aortic rings
Authors: Tatsuhiko Hirota
Atsuko Nonaka
Akiko Matsushita
Naoto Uchida
Kohji Ohki
Masanori Asakura
Masafumi Kitakaze
Publication date: 01-09-2011
Publisher: Springer Japan
Published in: Heart and Vessels / Issue 5/2011
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI: https://doi.org/10.1007/s00380-010-0096-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Milk casein-derived tripeptides, VPP and IPP induced NO production in cultured endothelial cells and endothelium-dependent relaxation of isolated aortic rings

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2011

Intravenous glutathione prevents renal oxidative stress after coronary angiography more effectively than oral N-acetylcysteine

Clinical analysis of the risk factors of slow coronary flow

Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up

Erratum to: Measurement of platelet reactivity of patients with cardiovascular disease on-treatment with acetyl salicylic acid: a prospective study

Higher body mass index at the time of acute myocardial infarction is associated with a favorable long-term prognosis (8-year follow-up)

Reversible course of pulmonary arterial hypertension related to bone marrow transplantation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page